Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis

OBJECTIVE: Renal cell carcinoma (RCC) is the most common type of kidney cancer. VEGF inhibitors and mTORs are the most common therapeutic options among the different classes of available treatments. In this study, the effectiveness of Everolimus was compared to Temsirolimus, and Everolimus plusLenva...

Descripción completa

Detalles Bibliográficos
Autores principales: Goudarzi, Zahra, Mostafavi, Mehrdad, Salesi, Mahmood, Jafari, Mojtaba, Mirian, Iman, Hashemi Meshkini, Amir, Keshavarz, Khosro, Ghasemi, Younes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878789/
https://www.ncbi.nlm.nih.gov/pubmed/36703202
http://dx.doi.org/10.1186/s12962-023-00420-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878789/
https://www.ncbi.nlm.nih.gov/pubmed/36703202
http://dx.doi.org/10.1186/s12962-023-00420-4

Ejemplares similares